BUY $CMRX
• Chimerix, a biopharmaceutical company, announced that its CEO, Mike Andriole, will present a corporate presentation at the H.C.
• Wainwright 26th Annual Global Investment Conference on September 9, 2024.
• The presentation will be made available on Monday, September 9, 2024 at 7:00 a.m.
• An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website..
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at www.ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACT:
Will O’Connor
Stern Investor Relations
212-362-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.
BUY $CMRX
| Last Trade: | US$0.85 |
| Daily Change: | -0.0001 -0.01 |
| Daily Volume: | 148,969 |
| Market Cap: | US$76.630M |
August 13, 2024 August 06, 2024 April 24, 2024 | |
BUY $CMRX
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE